729 related articles for article (PubMed ID: 15664565)
1. Botulinum toxin A (Botox) and sweating-dose efficacy and comparison to other BoNT preparations.
Schlereth T; Mouka I; Eisenbarth G; Winterholler M; Birklein F
Auton Neurosci; 2005 Feb; 117(2):120-6. PubMed ID: 15664565
[TBL] [Abstract][Full Text] [Related]
2. Dose thresholds and duration of the local anhidrotic effect of botulinum toxin injections: measured by sudometry.
Braune C; Erbguth F; Birklein F
Br J Dermatol; 2001 Jan; 144(1):111-7. PubMed ID: 11167691
[TBL] [Abstract][Full Text] [Related]
3. Botulinum toxin type B blocks sudomotor function effectively: a 6 month follow up.
Birklein F; Eisenbarth G; Erbguth F; Winterholler M
J Invest Dermatol; 2003 Dec; 121(6):1312-6. PubMed ID: 14675175
[TBL] [Abstract][Full Text] [Related]
4. Pain sensation during intradermal injections of three different botulinum toxin preparations in different doses and dilutions.
Kranz G; Sycha T; Voller B; Gleiss A; Schnider P; Auff E
Dermatol Surg; 2006 Jul; 32(7):886-90. PubMed ID: 16875469
[TBL] [Abstract][Full Text] [Related]
5. Effect of botulinum toxin concentration on reduction in sweating: a randomized, double-blind study.
Rystedt A; Karlqvist M; Bertilsson M; Naver H; Swartling C
Acta Derm Venereol; 2013 Nov; 93(6):674-8. PubMed ID: 23694974
[TBL] [Abstract][Full Text] [Related]
6. Anhidrotic effect of intradermal injections of botulinum toxin: a comparison of different products and concentrations.
Rystedt A; Swartling C; Naver H
Acta Derm Venereol; 2008; 88(3):229-33. PubMed ID: 18480920
[TBL] [Abstract][Full Text] [Related]
7. Sudomotor testing predicts the presence of neutralizing botulinum A toxin antibodies.
Birklein F; Walther D; Bigalke H; Winterholler M; Erbguth F
Ann Neurol; 2002 Jul; 52(1):68-73. PubMed ID: 12112049
[TBL] [Abstract][Full Text] [Related]
8. Same-patient prospective comparison of Botox versus Dysport for the treatment of primary axillary hyperhidrosis and review of literature.
Vergilis-Kalner IJ
J Drugs Dermatol; 2011 Sep; 10(9):1013-5. PubMed ID: 22052270
[TBL] [Abstract][Full Text] [Related]
9. Pharmacology of botulinum toxin: differences between type A preparations.
Rosales RL; Bigalke H; Dressler D
Eur J Neurol; 2006 Feb; 13 Suppl 1():2-10. PubMed ID: 16417591
[TBL] [Abstract][Full Text] [Related]
10. Botulinum toxin type B vs. type A in toxin-naïve patients with cervical dystonia: Randomized, double-blind, noninferiority trial.
Pappert EJ; Germanson T;
Mov Disord; 2008 Mar; 23(4):510-7. PubMed ID: 18098274
[TBL] [Abstract][Full Text] [Related]
11. Long-term efficacy and respective potencies of botulinum toxin A and B: a randomized, double-blind study.
Kranz G; Paul A; Voller B; Posch M; Windischberger C; Auff E; Sycha T
Br J Dermatol; 2011 Jan; 164(1):176-81. PubMed ID: 21039405
[TBL] [Abstract][Full Text] [Related]
12. Botulinum toxin type B in antibody-induced botulinum toxin type A therapy failure.
Dressler D; Bigalke H; Benecke R
J Neurol; 2003 Aug; 250(8):967-9. PubMed ID: 12928917
[TBL] [Abstract][Full Text] [Related]
13. Botulinum Toxin A reduces neurogenic flare but has almost no effect on pain and hyperalgesia in human skin.
Krämer HH; Angerer C; Erbguth F; Schmelz M; Birklein F
J Neurol; 2003 Feb; 250(2):188-93. PubMed ID: 12574949
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of botulinum toxin type B for the treatment of primary palmar hyperhidrosis: a prospective, open, single-blind, multi-centre study.
Basciani M; Di Rienzo F; Bizzarrini M; Zanchi M; Copetti M; Intiso D
Arch Dermatol Res; 2014 Jul; 306(5):497-503. PubMed ID: 24522897
[TBL] [Abstract][Full Text] [Related]
15. Different types of botulinum toxin in humans.
Eleopra R; Tugnoli V; Quatrale R; Rossetto O; Montecucco C
Mov Disord; 2004 Mar; 19 Suppl 8():S53-9. PubMed ID: 15027055
[TBL] [Abstract][Full Text] [Related]
16. A double-blind, randomized, comparative study of Dysport vs. Botox in primary palmar hyperhidrosis.
Simonetta Moreau M; Cauhepe C; Magues JP; Senard JM
Br J Dermatol; 2003 Nov; 149(5):1041-5. PubMed ID: 14632812
[TBL] [Abstract][Full Text] [Related]
17. Comparing two botulinum toxin type A formulations using manufacturers' product summaries.
Wenzel R; Jones D; Borrego JA
J Clin Pharm Ther; 2007 Aug; 32(4):387-402. PubMed ID: 17635341
[TBL] [Abstract][Full Text] [Related]
18. Comparison of botulinum neurotoxin preparations for the treatment of cervical dystonia.
Chapman MA; Barron R; Tanis DC; Gill CE; Charles PD
Clin Ther; 2007 Jul; 29(7):1325-37. PubMed ID: 17825685
[TBL] [Abstract][Full Text] [Related]
19. [Botulinum toxin in the treatment of focal hyperhidrosis].
Schnider P; Moraru E; Kittler H; Voller B; Kranz G; Auff E
Wien Klin Wochenschr; 2001; 113 Suppl 4():36-41. PubMed ID: 15506051
[TBL] [Abstract][Full Text] [Related]
20. The broadening application of chemodenervation in X-linked dystonia-parkinsonism (Part I): muscle afferent block versus botulinum toxin-A in cervical and limb dystonias.
Rosales RL; Santos MM; Ng AR; Teleg R; Dantes M; Lee LV; Fernandez HH
Int J Neurosci; 2011; 121 Suppl 1():35-43. PubMed ID: 21244305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
